

## Capital adequacy ratios and regulatory capital disclosures

### Regulatory capital disclosures

|   | Component of regulatory capital   | Cross-reference to financial position reconciliation |
|---|---|--|
|   | At 30-Jun-2016  |  |
|   | US\$  |  |
| <b>CET1 capital: instruments and reserves</b> |   |  |
| 1   | Directly issued qualifying CET1 capital instruments plus any related share premium  | 3  |
| 2   | Retained earnings   | 5+6+7  |
| 3   | Disclosed reserves  | 8  |
| 4   | <i>Directly issued capital subject to phase out from CET1 capital (only applicable to non-joint stock companies)</i>  | Not applicable                                       |
| 5   | Minority interests arising from CET1 capital instruments issued by consolidated bank subsidiaries and held by third parties (amount allowed in CET1 capital of the consolidation group) | 0  |
| 6   | <b>CET1 capital before regulatory deductions</b>  |  |
|   | 248,197,429   |  |
| <b>CET1 capital: regulatory deductions</b>    |   |  |
| 7   | Valuation adjustments   | 0  |
| 8   | Goodwill (net of associated deferred tax liability)   | 0  |
| 9   | Other intangible assets (net of associated deferred tax liability)  | 0  |
| 10  | Deferred tax assets net of deferred tax liabilities   | 2  |
| 11  | Cash flow hedge reserve   | 0  |
| 12  | Excess of total EL amount over total eligible provisions under the IRB approach   | 0  |
| 13  | Gain-on-sale arising from securitization transactions   | 0  |
| 14  | Gains and losses due to changes in own credit risk on fair valued liabilities   | 0  |
| 15  | Defined benefit pension fund net assets (net of associated deferred tax liabilities)  | 0  |
| 16  | Investments in own CET1 capital instruments (if not already netted off paid-in capital on reported balance sheet)   | 0  |
| 17  | Reciprocal cross-holdings in CET1 capital instruments   | 0  |
| 18  | Insignificant capital investments in CET1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold)   | 0  |
| 19  | Significant capital investments in CET1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold)     | 0  |
| 20  | Mortgage servicing rights (amount above 10% threshold)  | Not applicable                                       |
| 21  | Deferred tax assets arising from temporary differences (amount above 10% threshold, net of related tax liability)   | Not applicable                                       |
| 22  | Amount exceeding the 15% threshold  | Not applicable                                       |
| 23  | of which: significant investments in the common stock of financial sector entities  | Not applicable                                       |
| 24  | of which: mortgage servicing rights   | Not applicable                                       |
| 25  | of which: deferred tax assets arising from temporary differences  | Not applicable                                       |
| 26  | National specific regulatory adjustments applied to CET1 capital  |  |
|   | 889,595   |  |
| 26a   | Regulatory reserve for general banking risks  | 6  |
|   | 889,595   |  |
| 27  | Regulatory deductions applied to CET1 capital due to insufficient AT1 capital and Tier 2 capital to cover deductions  | 0  |
| 28  | <b>Total regulatory deductions to CET1 capital</b>  |  |
|   | 4,710,582   |  |
| 29  | <b>CET1 capital</b>   |  |
|   | 243,486,847   |  |
| <b>AT1 capital: instruments</b>               |   |  |
| 30  | Qualifying AT1 capital instruments plus any related share premium   | 0  |
| 31  | of which: classified as equity under applicable accounting standards  | 0  |
| 32  | of which: classified as liabilities under applicable accounting standards   | 0  |
| 33  | <i>Capital instruments subject to phase out arrangements from AT1 capital</i>   | 0  |
| 34  | AT1 capital instruments issued by consolidated bank subsidiaries and held by third parties (amount allowed in AT1 capital of the consolidation group)                                   | 0  |
| 35  | <i>of which: AT1 capital instruments issued by subsidiaries subject to phase out arrangements</i>   | 0  |
| 36  | <b>AT1 capital before regulatory deductions</b>   | 0  |

## Capital adequacy ratios and regulatory capital disclosures

### Regulatory capital disclosures

|   | Component of regulatory capital   | Cross-reference to financial position reconciliation |     |
|---|---|--|-----|
|   | At 30-Jun-2016  |  |     |
|   | US\$  |  |     |
| <b>AT1 capital: regulatory deductions</b>                       |   |  |     |
| 37  | Investments in own AT1 capital instruments  | 0  |     |
| 38  | Reciprocal cross-holdings in AT1 capital instruments  | 0  |     |
| 39  | Insignificant capital investments in AT1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold)                                  | 0  |     |
| 40  | Significant capital investments in AT1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation   | 0  |     |
| 41  | National specific regulatory adjustments applied to AT1 capital   | 0  |     |
| 42  | Regulatory deductions applied to AT1 capital due to insufficient Tier 2 capital to cover deductions   | 0  |     |
| 43  | <b>Total regulatory deductions to AT1 capital</b>   | 0  |     |
| 44  | <b>AT1 capital</b>  | 0  |     |
| 45  | <b>Tier 1 capital (Tier 1 = CET1 + AT1)</b>   | 243,486,847  |     |
| <b>Tier 2 capital: instruments and provisions</b>               |   |  |     |
| 46  | Qualifying Tier 2 capital instruments plus any related share premium  | 0  |     |
| 47  | <i>Capital instruments subject to phase out arrangements from Tier 2 capital</i>  | 0  |     |
| 48  | Tier 2 capital instruments issued by consolidated bank subsidiaries and held by third parties (amount allowed in Tier 2 capital of the consolidation group)   | 0  |     |
| 49  | <i>of which: capital instruments issued by subsidiaries subject to phase out arrangements</i>   | 0  |     |
| 50  | Collective impairment allowances and regulatory reserve for general banking risks eligible for inclusion in Tier 2 capital  | 4,682,077  | 1+6 |
| 51  | <b>Tier 2 capital before regulatory deductions</b>  | 4,682,077  |     |
| <b>Tier 2 capital: regulatory deductions</b>                    |   |  |     |
| 52  | Investments in own Tier 2 capital instruments   | 0  |     |
| 53  | Reciprocal cross-holdings in Tier 2 capital instruments   | 0  |     |
| 54  | Insignificant capital investments in Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold)                               | 0  |     |
| 55  | Significant capital investments in Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation  | 0  |     |
| 56  | National specific regulatory adjustments applied to Tier 2 capital  | 0  |     |
| 57  | <b>Total regulatory deductions to Tier 2 capital</b>  | 0  |     |
| 58  | <b>Tier 2 capital</b>   | 4,682,077  |     |
| 59  | <b>Total capital (Total capital = Tier 1 + Tier 2)</b>  | 248,168,924  |     |
| 60  | <b>Total risk weighted assets</b>   | 922,069,039  |     |
| <b>Capital ratios (as a percentage of risk weighted assets)</b> |   |  |     |
| 61  | CET1 capital ratio  | 26.41%   |     |
| 62  | Tier 1 capital ratio  | 26.41%   |     |
| 63  | Total capital ratio   | 26.91%   |     |
| 64  | Institution specific buffer requirement (minimum CET1 capital requirement as specified in s.3B of the BCR plus capital conservation buffer plus countercyclical buffer requirements plus G-SIB or D-SIB requirements) | 5.3750%  |     |
| 65  | <i>of which: capital conservation buffer requirement</i>  | 0.00%  |     |
| 66  | <i>of which: bank specific countercyclical buffer requirement</i>   | 0.00%  |     |
| 67  | <i>of which: G-SIB or D-SIB buffer requirement</i>  | 0.00%  |     |
| 68  | CET1 capital surplus over the minimum CET1 requirement and any CET1 capital used to meet the Tier 1 and Total capital requirement under s.3B of the BCR   | 0.00%  |     |
| <b>National minima (if different from Basel 3 minimum)</b>      |   |  |     |
| 69  | National CET1 minimum ratio   | Not applicable                                       |     |
| 70  | National Tier 1 minimum ratio   | Not applicable                                       |     |
| 71  | National Total capital minimum ratio  | Not applicable                                       |     |

## Capital adequacy ratios and regulatory capital disclosures

### Regulatory capital disclosures

|   |  | Component of regulatory capital                            | Cross-reference to financial position reconciliation |
|---|--|--|--|
|   |  | At 30-Jun-2016   |  |
|   |  | US\$   |  |
| <b>Amounts below the thresholds for deduction (before risk weighting)</b> |  |  |  |
| 72  | Insignificant capital investments in CET1 capital instruments, AT1 capital instruments and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation | 0  |  |
| 73  | Significant capital investments in CET1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation   | 0  |  |
| 74  | Mortgage servicing rights (net of related tax liability)   | Not applicable   |  |
| 75  | Deferred tax assets arising from temporary differences (net of related tax liability)  | Not applicable   |  |
| <b>Applicable caps on the inclusion of provisions in Tier 2 capital</b>   |  |  |  |
| 76  | Provisions eligible for inclusion in Tier 2 in respect of exposures subject to the basic approach and the standardized (credit risk) approach (prior to application of cap)                                      | 0  |  |
| 77  | Cap on inclusion of provisions in Tier 2 under the basic approach and the standardized (credit risk) approach  | 0  |  |
| 78  | Provisions eligible for inclusion in Tier 2 in respect of exposures subject to the IRB approach (prior to application of cap)  | 0  |  |
| 79  | Cap for inclusion of provisions in Tier 2 under the IRB approach   | 0  |  |
| <b>Capital instruments subject to phase-out arrangements</b>              |  | <b>(only applicable between 1 Jan 2018 and 1 Jan 2022)</b> |  |
| 80  | Current cap on CET1 capital instruments subject to phase out arrangements  | Not applicable   |  |
| 81  | Amount excluded from CET1 due to cap (excess over cap after redemptions and maturities)  | Not applicable   |  |
| 82  | Current cap on AT1 capital instruments subject to phase out arrangements   | 0  |  |
| 83  | Amount excluded from AT1 capital due to cap (excess over cap after redemptions and maturities)   | 0  |  |
| 84  | Current cap on Tier 2 capital instruments subject to phase out arrangements  | 0  |  |
| 85  | Amount excluded from Tier 2 capital due to cap (excess over cap after redemptions and maturities)  | 0  |  |

#### Notes:

Elements where a more conservative definition has been applied in the BCR relative to that set out in Basel III capital standards:

| Row No. | Description   | Hong Kong basis (USD) | Basel III basis (USD) |
|---------|---|-----------------------|-----------------------|
|         | <b>Deferred tax assets net of deferred tax liabilities</b>  | 3,820,987             | 0                     |
| 10      | <p><u>Explanation</u></p> <p>As set out in paragraphs 69 and 87 of the Basel III text issued by the Basel Committee (December 2010), DTAs that rely on future profitability of the bank to be realized are to be deducted, whereas DTAs which relate to temporary differences may be given limited recognition in CET1 capital (and hence be excluded from deduction from CET1 capital up to the specified threshold). In Hong Kong, an AI is required to deduct all DTAs in full, irrespective of their origin, from CET1 capital. Therefore, the amount to be deducted as reported in row 10 may be greater than that required under Basel III.</p> <p>The amount reported under the column "Basel III basis" in this box represents the amount reported in row 10 (i.e. the amount reported under the "Hong Kong basis") adjusted by reducing the amount of DTAs to be deducted which relate to temporary differences to the extent not in excess of the 10% threshold set for DTAs arising from temporary differences and the aggregate 15% threshold set for MSRs, DTAs arising from temporary differences and significant investments in CET1 capital instruments issued by financial sector entities (excluding those that are loans, facilities and other credit exposures to connected companies) under Basel III.</p> |                       |                       |

#### Abbreviations:

CET1: Common Equity Tier 1

AT1: Additional Tier 1

## Capital adequacy ratios and regulatory capital disclosures (continued)

### Financial position reconciliation

|   | At 30-Jun-2016       | Cross Reference<br>to Definition of<br>Capital<br>Components |
|---|----------------------|--|
|   | US\$                 |  |
| <b>ASSETS</b>   |                      |  |
| Cash and balances with banks and other financial institutions   | 33,151,492           |  |
| Placements with banks and other financial institutions  | 87,000,000           |  |
| Trade bills   | 161,403,867          |  |
| Trading assets  | 39,483,325           |  |
| Loans and advances  | 462,952,334          |  |
| <i>of which: collective impairment allowances reflected in regulatory capital</i>                           | 3,792,482            | 1  |
| Available-for-sale investments  | 416,548,142          |  |
| Property and equipment  | 1,189,520            |  |
| Interest receivable and other assets  | 13,609,679           |  |
| Deferred tax assets   | 1,976,691            |  |
| <i>of which: Deferred tax assets related to property and equipment and collective impairment allowances</i> | 3,820,987            | 2  |
| <b>TOTAL ASSETS</b>   | <b>1,217,315,050</b> |  |
| <b>EQUITY AND LIABILITIES</b>   |                      |  |
| <b>LIABILITIES</b>  |                      |  |
| Deposits and balances of banks and other financial institutions   | 472,000,000          |  |
| Deposits from customers   | 3,537,704            |  |
| Trading liabilities   | 3,893,537            |  |
| Certificates of deposit issued  | 425,090,725          |  |
| Tax payable   | 2,372,644            |  |
| Interest payable and other liabilities  | 62,223,011           |  |
| <b>TOTAL LIABILITIES</b>  | <b>969,117,621</b>   |  |
| <b>EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY</b>   |                      |  |
| Share capital   | 140,000,000          | 3  |
| Reserves  | 108,197,429          | 4  |
| <i>of which: Retained profits</i>   | 87,289,743           | 5  |
| <i>    : Regulatory reserve</i>   | 889,595              | 6  |
| <i>    : Current profit/(loss)</i>  | 10,221,676           | 7  |
| <i>    : accumulated other comprehensive income</i>   | 9,796,415            | 8  |
| <b>TOTAL EQUITY</b>   | <b>248,197,429</b>   |  |
| <b>TOTAL EQUITY AND LIABILITIES</b>   | <b>1,217,315,050</b> |  |

## Capital adequacy ratios and regulatory capital disclosures (continued)

### Main features of outstanding regulatory capital instrument

|    |   |   |
|----|---|---|
| 1  | Issuer  | KDB Asia Limited  |
| 2  | Unique identifier (eg CUSIP, ISIN or Bloomberg identifier for private placement)                              | Not Applicable  |
| 3  | Governing law(s) of the instrument  | Hong Kong Special Administrative Region of the People's Republic of China   |
|    | <i>Regulatory treatment</i>   |   |
| 4  | Transitional Basel III rules <sup>#</sup>   | Not Applicable  |
| 5  | Post-transitional Basel III rules <sup>+</sup>  | Common Equity Tier 1  |
| 6  | Eligible at solo*/group/group & solo  | Solo  |
| 7  | Instrument type (types to be specified by each jurisdiction)  | Ordinary shares   |
| 8  | Amount recognised in regulatory capital (Currency in million, as of most recent reporting date)               | US\$ 140 Million  |
| 9  | Par value of instrument   | US\$ 1 each   |
| 10 | Accounting classification   | Shareholders' equity  |
| 11 | Original date of issuance   | 23 Feb 2007 (US\$ 50 Million)<br>18 Mar 2005 (US\$ 20 Million)<br>24 Jul 2002 (US\$ 10 Million)<br>20 Sep 1999 (US\$ 25 Million)<br>29 Mar 1995 (US\$ 20 Million)<br>5 Mar 1990 (US\$ 5 Million)<br>20 Jan 1986 (US\$ 10 Million) |
| 12 | Perpetual or dated  | Perpetual   |
| 13 | Original maturity date  | Not Applicable  |
| 14 | Issuer call subject to prior supervisory approval   | Not Applicable  |
| 15 | Optional call date, contingent call dates and redemption amount   | Not Applicable  |
| 16 | Subsequent call dates, if applicable  | Not Applicable  |
|    | <i>Coupons / dividends</i>  |   |
| 17 | Fixed or floating dividend/coupon   | Floating  |
| 18 | Coupon rate and any related index   | Not Applicable  |
| 19 | Existence of a dividend stopper   | Not Applicable  |
| 20 | Fully discretionary, partially discretionary or mandatory   | Fully discretionary   |
| 21 | Existence of step up or other incentive to redeem   | Not Applicable  |
| 22 | Noncumulative or cumulative   | Noncumulative   |
| 23 | Convertible or non-convertible  | Non-convertible   |
| 24 | If convertible, conversion trigger (s)  | Not Applicable  |
| 25 | If convertible, fully or partially  | Not Applicable  |
| 26 | If convertible, conversion rate   | Not Applicable  |
| 27 | If convertible, mandatory or optional conversion  | Not applicable  |
| 28 | If convertible, specify instrument type convertible into  | Not applicable  |
| 29 | If convertible, specify issuer of instrument it converts into   | Not Applicable  |
| 30 | Write-down feature  | No  |
| 31 | If write-down, write-down trigger(s)  | Not Applicable  |
| 32 | If write-down, full or partial  | Not Applicable  |
| 33 | If write-down, permanent or temporary   | Not applicable  |
| 34 | If temporary write-down, description of write-up mechanism  | Not Applicable  |
| 35 | Position in subordination hierarchy in liquidation (specify instrument type immediately senior to instrument) | Not Applicable  |
| 36 | Non-compliant transitioned features   | No  |
| 37 | If yes, specify non-compliant features  | Not Applicable  |

#### Footnote:

<sup>#</sup> Regulatory treatment of capital instruments subject to transitional arrangements provided for in Schedule 4H of the Banking (Capital) Rules

<sup>+</sup> Regulatory treatment of capital instruments not subject to transitional arrangements provided for in Schedule 4H of the Banking (Capital) Rules

\* Include solo-consolidated